Business Context and Reporting Period
The supplied filing is a Form 10-K for Nile Therapeutics, Inc., not Capricor Therapeutics, Inc. It covers the fiscal year ended December 31, 2011 and was filed April 2, 2012. Nile was a development-stage biopharmaceutical company focused on cardiovascular and renal diseases, principally heart failure.
The lead candidate was cenderitide, in clinical development for post-acute heart failure treatment. CU-NP remained preclinical. The company had no approved products or recurring product revenue.
Key Financial Metrics
| Metric | 2011 | 2010 |
|---|---|---|
| Product revenue | None | None |
| Collaboration income | $1.355 million | None |
| Total operating expenses | $6.254 million | $6.294 million |
| Research and development expense | $4.137 million | $4.081 million |
| General and administrative expense | $2.117 million | $2.213 million |
| Loss from operations | $4.899 million | $6.294 million |
| Net loss | $4.885 million | $6.031 million |
| Basic and diluted loss per share | $0.13 loss | $0.19 loss |
| Cash used in operating activities | $4.649 million | $4.318 million |
| Cash and cash equivalents at year-end | $1.039 million | $3.378 million |
| Working capital | $0.769 million | $2.528 million |
| Stockholders’ equity | $0.831 million | $2.597 million |
The filing does not identify material long-term debt outstanding at December 31, 2011. Current liabilities totaled approximately $0.541 million, including accounts payable of $0.438 million. The company had an accumulated development-stage deficit of $44.815 million.
Operating margin and net margin are not meaningful because the company had no product revenue and reported operating and net losses.
Material Changes Versus the Prior Comparable Period
- Net loss improved by approximately $1.147 million, primarily because 2011 included $1.355 million of Medtronic collaboration income.
- Cash declined by approximately $2.339 million, from $3.378 million to $1.039 million.
- Operating cash usage increased by approximately $0.331 million.
- R&D expense was broadly stable: increased spending on cenderitide subcutaneous studies offset lower spending on the prior Phase 2 ADHF trial.
- G&A expense decreased modestly by approximately $0.096 million.
- The company raised approximately $2.299 million net from a June 2011 private placement of common stock and warrants.
- Shares outstanding increased to 39.712 million at December 31, 2011 from 34.630 million at December 31, 2010, creating dilution risk.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management planned to initiate a Phase 2 cenderitide study in mid-2012, subject to financing. The planned study could include up to 296 patients, cost approximately $15 million to $20 million, and take about 30 months.
- Management expected 2012 cenderitide development spending of approximately $2.0 million to $2.5 million, including $0.5 million to $1.0 million of external manufacturing and toxicology costs.
- At year-end, available cash was insufficient to fund the planned Phase 2 study. Management stated that existing resources, together with expected proceeds from a March 2012 financing, would fund general corporate activities only into the fourth quarter of 2012.
- The auditors and management disclosed substantial doubt about the company’s ability to continue as a going concern. Additional equity, debt, collaboration, or licensing financing was required.
- On March 30, 2012, the company agreed to sell 3.350 million shares and warrants to purchase 2.5125 million shares for gross proceeds of approximately $1.34 million, before estimated offering costs of approximately $0.2 million.
- Medtronic reimbursed approximately $1.355 million of expenses related to the 58-patient Phase 1 cenderitide study. The collaboration agreement expired in February 2012.
- The 2011 Phase 1 study achieved its primary pharmacokinetic endpoint and reported that subcutaneous delivery was tolerated, but the product remained unapproved and required additional clinical testing.
- Key risks include clinical-trial failure or delay, regulatory rejection, adverse effects including hypotension, dependence on third-party manufacturers and collaborators, intellectual-property risks, intense competition, and inability to raise capital.
- The company relied substantially on Two River Consulting, an affiliate of certain officers and directors, for management and operational services. Related-party payments totaled approximately $0.529 million in 2011, and $0.039 million was payable at year-end and paid in January 2012.
- The common stock moved from the NASDAQ Capital Market to the OTCQB in May 2011 and was classified as a penny stock, increasing liquidity and trading risks.
Investor Verification Checklist
- Verify the issuer identity: the supplied text identifies Nile Therapeutics, Inc., while the request identifies Capricor Therapeutics, Inc.
- Verify completion and net proceeds of the March/April 2012 financing and the resulting share and warrant dilution.
- Verify current cash runway, going-concern disclosures, and whether additional financing or a strategic partner was obtained.
- Review the full audited financial statements and notes for clinical accruals, stock-based compensation, licensing commitments, and warrant overhang.
- Assess whether the planned cenderitide Phase 2 trial commenced, its funding source, enrollment, endpoints, and subsequent clinical results.
- Review the status of Mayo license agreements, milestone obligations, royalties, patent coverage, and termination provisions.
- Evaluate related-party arrangements with Two River Consulting and Riverbank Capital Securities.